Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.
9,580.3090.2
Stock Analysis, IPO, Mutual Funds, Bonds & More

Cadila Healthcare Ltd.

AllNewsAnnouncementRecos

BSE LIVE

Change:

Volume:

Open:

Prv. Close:

Today:

Cadila Healthcare Ltd.

52-Wk:

Cadila Healthcare Ltd.

Bid:

()

Offer:

()

NSE LIVE

Change:

Volume:

Open:

Prv. Close:

Today:

Cadila Healthcare Ltd.

52-Wk:

Cadila Healthcare Ltd.

Bid:

()

Offer:

()

A total of 156,390 shares changed hands on the counter till 10:42AM (IST).

Google is said to be exploring taking a minority stake in British telecom group Vodafone’s struggling India business.

Cadila Healthcare Updates

| Announcement

As per the attached letter

The Nifty Pharma index was trading 1.21 per cent down at 9484.35.

Cadila Healthcare Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Zydus supplies first batch of 30,000 COVID KAVACH ELISA tests to ICMR, free of cost

The Nifty Pharma index was trading 0.57 per cent down at 9041.6.

Cadila Healthcare Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Zydus Cadila receives tentative approval from USFDA for Droxidopa Capsules, 100 mg, 200 mg, and 300 mg

The Nifty Pharma index was trading 1.01 per cent up at 9240.55.

Cadila Healthcare Compliance For The Half Year Ended On On March 31, 2020.

| Announcement

Compliance for the half year ended on on March 31, 2020.

Cadila Healthcare Audited Financial Results

| Announcement

The Company shall approve the audited financial results for the quarter / year ended on March 31, 2020 on or before June 30, 2020.

Cadila Healthcare Statement Of Investor Complaints For The Quarter Ended March 2020

| Announcement

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Dhaval N Soni
Designation :- Company Secretary and Compliance Officer

Cadila Healthcare COVID-19 Testing

| Announcement

COVID-19 testing

"Our aim is to make a preferred choice of therapy like Obynx available and more accessible to people suffering from cancer. Bridging these unmet gaps comes from our patient-first approach," Zydus Cadila MD Sharvil Patel told .

Cadila Healthcare Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Zydus Cadila Launches Enzalutamide, making Prostate Cancer therapy highly affordable

Shares of Cadila Healthcare Ltd. traded 0.86 per cent down in trade at 11:31AM on Friday .

Nifty Pharma is up 12.4 per cent since February while Nifty is down 23.1 %

Cadila Healthcare Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Zydus Cadila receives final approval from USFDA for Deferasirox Tablets for Oral Suspension

Cadila Healthcare Updates

| Announcement

Update COVID-19

Shares of Cadila Healthcare traded 2.79 per cent up in trade at 10:55AM on Monday.

Cadila Healthcare Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Zydus receives tentative approval from the USFDA for Empagliflozin and Metformin Hydrochloride Tablets

Cadila Healthcare Certificate Under Regulation 40(10) Of SEBI Listing Regulations, 2015

| Announcement

Certificate under Regulation 40(10) of SEBI Listing Regulations, 2015

Cadila Healthcare Announcement under Regulation 30 (LODR)-Diversification / Disinvestment

| Announcement

Divestment of 49% shares of Windlas Healthcare Private Limited.

Cadila Healthcare Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

| Announcement

Certificate under Reg. 74(5) of SEBI (DIP) Regulations, 2018

The brokerage expects Cadila to report an ~8% year on year decline in revenue to Rs 34 billion.

The BSE Healthcare index is up nearly 9% since February. In comparison, the Sensex is down 22% since February.

Fifty pharmaceutical manufacturing facilities have shuttered their operations in Baddi, Himachal Pradesh, Asia’s largest pharmaceutical hub, while others are operating at significantly reduced capacities after the region was declared a containment zone.

Cadila Healthcare Shareholding for the Period Ended March 31, 2020

| Announcement

Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here

Cadila Healthcare Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Zydus explores the biologicals route to treat novel Coronavirus with long-acting Interferon alpha-2b

Cadila Healthcare Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Zydus receives final approval from the USFDA for Baclofen Tablets

The Nifty Pharma index was trading 0.84 per cent down at 9121.65.

Cadila Healthcare Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Zydus receives final approval from the USFDA for Erlotinib Tablets

Cadila Healthcare Announcement under Regulation 30 (LODR)-Diversification / Disinvestment

| Announcement

Sale of 2% shares of Windlas Healthcare Private Limited, a subsidiary company.

This will be the second online conference that Bennett University will be organising in less than a week. At a time when leading research labs, think tanks and universities are pooling their resources together to find the best possible way to contain the Covid-19 pandemic, this online conference will aim to explore the possibilities in biotechnology which could assist in combating the pandemic.

India's decision to sell the sought-after drug to Malaysia signals a turnaround in relations between the countries that had soured because of repeated criticism of some Indian policies by Mahathir Mohamad, before he resigned as Malaysia's prime minister in February.

Cadila Healthcare Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Zydus receives tentative approval from the USFDA for the Macitentan tablets

The Nifty Pharma index was trading 3.27 per cent up at 9340.3 .

The drugmaker is one of the two largest manufacturers of hydroxychloroquine (HCQ).

HDFC twins and Reliance Industries were among the biggest drags, but a jump in L&T after three ‘large’ order wins cushion the fall to some extent.

The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The sector has managed to function during the lockdown and meet local and global demand.

Other useful Links


Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service